BOOKMARK
  • Korean|
  • Chinese|
  • Japanese|
  • Vietnamese
본문내용 바로가기

Aju Business Daily

SEARCH
  • ECONOMY
  • ENTERTAINMENT
  • IT
  • South Korea
  • North Korea
  • WORLD
  • SPORTS
  • LIFESTYLE
  • AUTO MOTIVE
  • OPINION
  • PEOPLE
  • MILITARY
Home > Health > article

SK Bioscience ready to embark on second vaccine's clinical trials

Lim Chang-won Reporter(cwlim34@ajunews.com) | Posted : December 10, 2020, 08:32 | Updated : December 10, 2020, 08:32
  • 트위터
  • 페이스북
  • 웨이보

[Courtesy of SK Bioscience]

SEOUL -- SK Bioscience, a partner for South Korea's state project to develop COVID-19 vaccines, has applied for state approval to carry out clinical trials after its second vaccine candidate code-named GBP510 was selected to receive funding from an international foundation which finances vaccine research projects.

SK Bioscience hopes to embark on clinical trials in December to evaluate the safety and immunogenicity of GBP510, which is under development in a joint research project with the Institute for Protein Design at the University of Washington in Seattle. The vaccine candidate awaits approval from the Ministry of Food and Drug Safety.

"We are using our differentiated vaccine platform to discover a number of COVID-19 vaccine candidates and produce the best one," SK Bioscience CEO Ahn Jae-yong said in a statement on December 9. "Our goal is to create a COVID-19 vaccine with well-proven safety and effectiveness."

GBP510 has been selected for vaccine development by the Coalition for Epidemic Preparedness Innovations (CEPI), a foundation that takes donations to finance independent research projects to develop vaccines. It was the first case since CEPI launched its Wave 2 project in November to discover new vaccines with money from the Bill & Melinda Gates Foundation.

The Wave 2 project is aimed at finding universal and economical candidate materials that are easy to store and improve the number of inoculations, productivity and immune response. SK Bioscience will be able to receive $10 million from CEPI for clinical trials. If development is successful, the new vaccine will be distributed worldwide through international organizations.

SK Bioscience's first vaccine candidate called NBP2001 is in the first phase of clinical trials at a state-run hospital. NBP2001 is a recombinant vaccine manufactured from the virus' surface antigen protein through genetic combination. The surface antigen protein stimulates immune cells to induce immune responses.

SK Bioscience has promised to develop safe vaccines through the protein culture and refining platform of an antigen produced with gene recombination technology. The company has already succeeded in developing candidate substances for a cervical cancer vaccine through the same synthetic antigen method and completed second-stage clinical trials.

The Korea National Institute of Health, a state research body, has selected SK Bioscience as a cooperation partner to develop vaccines and medicine. SK Bioscience has a production partnership with AstraZeneca PLC, a Swedish-British pharmaceutical company which has announced positive results from late-stage trials of a coronavirus vaccine.

In August, SK Bioscience secured a deal to produce the antigen of a vaccine candidate being developed by Novavax, an American vaccine development company, that would be supplied in South Korea and globally if it proves to be safe and effective through clinical trials. Novavax is undergoing clinical trials for its vaccine candidate, NVX-CoV2373.

  • Lim Chang-won Reporter
  • email : cwlim34@ajunews.com
© Aju Business Daily & www.ajunews.com Copyright: All materials on this site may not be reproduced, distributed, transmitted, displayed, published or broadcast without the authorization from the Aju News Corporation.
  • twitter
  • facebook
  • weibo
  • link copy
  • LIST
  • TOP

Related news

  • .[INTERVIEW] Sugentech predicts modest sales after development of vaccines .
    [INTERVIEW] Sugentech predicts modest sales after developmen…
  • .SK Bioscience embarks on clinical test of COVID-19 vaccine candidate NBP2001 .
    SK Bioscience embarks on clinical test of COVID-19 vaccine c…
  • .SK Bioscience agrees to produce antigen of Novavax COVID-19 vaccine candidate.
    SK Bioscience agrees to produce antigen of Novavax COVID-19 …
  • .LSK Global PS to conduct third-stage clinical test of Chinese vaccine in Bangladesh.
    LSK Global PS to conduct third-stage clinical test of Chines…
  • .S. Korea unveils practical goal to vaccinate 70% of population.
    S. Korea unveils practical goal to vaccinate 70% of populati…

Real Time Photo News

  • .Singer HyunA to end 14-month hiatus with mini-album Im Not Cool.

    Singer HyunA to end 14-month hiatus with mini-album 'I'm Not Cool'

  • .NCSofts global K-pop fan community platform to service original content including songs.

    NCSoft's global K-pop fan community platform to service original content including songs

  • .Singer IU drops teaser image for upcoming full album.

    Singer IU drops teaser image for upcoming full album

  • .Cube Entertainment partners with web comics company to create online video content.

    Cube Entertainment partners with web comics company to create online video content

  • .Sci-fi film starring Song Joong-ki to be reelased on Netflix in February.

    Sci-fi film starring Song Joong-ki to be reelased on Netflix in February

Latest News

more+

  • LA-bound Maersk containership loses some 750 containers overboard in Pacific
  • SK Bioscience selected to manage COVID-19 vaccine distribution in S. Korea
  • S. Korea finalizes official process of imposing 513% tariff on imported rice
  • Verizon becomes first to deploy Samsung's fully virtualized 5G solutions
  • Singer HyunA to end 14-month hiatus with mini-album 'I'm Not Cool'
Aju Business Daily
  • ABOUT US
  • CONTACT US
  • PRIVACY STATEMENT
  • Copyright Policy

Address : Aju News Corporation LEEMA Building, 11th floor, 42, Jong-ro 1-gil, Jongno-gu, Seoul.    Mail : swatchsjp@ajunews.com

Copyright ⓒ 2016 By Ajunews Corporation, All Rights Reserved.

Mobile view